Your new post is loading...
GlaxoSmithKline’s quadrivalent influenza vaccine has been granted marketing authorisation in Germany and the UK. The four-strain vaccine is the first to be approved in a European country for active immunisation of adults and children from three years of age for the prevention of influenza disease caused by the two influenza A and two influenza B virus subtypes contained within the vaccine.
